News & Events

October 2018

Pantherna Therapeutics attended the BIO.NRW Business Angel ZIRKEL in Duesseldorf.

Dr. Gerrit Maaß, Chief Financial Officer, and Dr. Klaus Giese, Chief Executive Officer, were invited to outline the Company’s future strategy to develop mRNA-based therapeutics (PanRNA Therapeutics) for vascular diseases.

Pantherna Therapeutics participated as a finalist at BioRiver Boost! 2018 in Wuppertal.

The Company was presented by Dr. Klaus Giese, Chief Executive Officer, in a pitch session of selected finalists and Pantherna’s technology & business case was awarded a joint second place.

August 2018

Pantherna Therapeutics filed its first patent application “Recombinant nucleic acid construct”.

The patent filing of our ideas with confirming experimental data is a first milestone and signals an inflection point for Pantherna said Dr. Jörg Kaufmann, Chief Scientific Officer. “Now we can openly communicate Pantherna’s R&D strategy to develop novel mRNA constructs for optimized cell-type specific protein expression. Together with our extensive expertise and experience in the field of delivering nucleic acids to the vasculature Pantherna is now in a position to start its focused development campaign to test novel therapeutics modalities against several diseases with unmet medical need.”

April 2018

Pantherna Therapeutics presented at Biovaria in Munich.

Dr. Klaus Giese, Pantherna’s CEO, provided an overview of the Company’s R&D strategy.

March 2018

Pantherna Therapeutics contracted with the Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht.

Under this contract the Institute will generate and functionally evaluate mRNA constructs designed by Pantherna.

February 2018

Dr. Oliver Keil joined Pantherna Therapeutics as Chief Technology Officer.

Oliver is an experienced chemist with a long standing list of achievements in the field of drug delivery technologies, including the supervision of several CMC campaigns with liposomal-based nucleic acid inhibitors at Silence Therapeutics. His work opened the path to 2 clinical studies. Prior to Silence Therapeutics Oliver was instrumental in formulation work at G.O.T. Therapeutics focusing on liposomal-based drug-delivery systems for cytostatics and nucleic acids. Oliver received his Ph.D. at the University of Wuppertal.